Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a ...

Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) – Equities researchers at Wedbush issued their Q1 2026 earnings estimates for Sage Therapeutics in a report released on Wednesday ...

$50,000 of SAGE THERAPEUTICS lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Education and awareness of mental health ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the plug on the drug in Parkinson's disease. The decision, prompted by a ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

Medscape Medical News, October 09, 2024 Sage Therapeutics Scraps Alzheimer’s Drug Development After Trial Fails Sage Therapeutics said on Tuesday it would stop developing its experimental drug ...

Please enter a search term.

SAGE Stories was hosted in the Little Theatre of Saint Mary's, with readings by students and faculty of anonymous submissions ...